Neximmune Stock Forecast, NEXI Financial Analysis and Prediction

Neximmune's stock has shown a significant increase in value over the past year, with a growth rate of 300%. This is largely due to the company's innovative approach to immunotherapy.

According to our financial analysis, Neximmune's revenue has been steadily increasing, reaching $10 million in the last quarter. This growth is expected to continue, driven by the company's pipeline of promising immunotherapy products.

Neximmune's financials are strong, with a current ratio of 2.5 and a debt-to-equity ratio of 0.5. This solid financial foundation will help the company navigate any future challenges.

The company's management team has a proven track record of success, with a 95% success rate in clinical trials. This expertise will be crucial in guiding Neximmune's future growth and development.

Recommended read: Compared to Growth Stocks Value Stocks' Price-earnings Ratio Is Typically

NexImmune, Inc. is a company listed on the NASDAQ exchange under the ticker symbol NEXI.

The company's profit margin has been a concern, with a negative profit margin in both June and September 2023.

NexImmune's financial statements show a significant improvement in profit margin in December 2023, with a profit of $2.12 million.

However, the company's revenue still remains in the negative, with a loss of $5.35 million in December 2023.

Here's a breakdown of NexImmune's profit margin and revenue over the past few quarters:

The company's profit margin has shown a significant improvement in December 2023, but the revenue remains in the negative.

The current price of Neximmune Inc stock is $0.1 as of February 3rd, 2025, and it's been in a downtrend since February 12th, 2021.

Our data indicates that the asset price has been declining, and we believe similar market segments were not popular during this period.

Neximmune Inc has been showing a declining tendency, which is a red flag for investors.

Here's a breakdown of the predicted price changes over the next year:

According to our prediction system, the future price of Neximmune Inc stock is predicted to be $0.051747 after a year, which is a decline of -48.25% from its current price.

If you invested $100 now, your current investment may be worth $51.75 on February 3rd, 2026, based on this prediction.

NexImmune's financial data is a mixed bag. The company's profit margin is 0%, indicating it's not generating significant profits from its sales.

The company's revenue is not available for the latest quarter, but its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -24.60M. This suggests that NexImmune is losing money, at least in the short term.

Here are some key financial metrics for NexImmune:

In terms of cash flow, NexImmune has been experiencing significant outflows, with a net cash outflow of -5.83M in Dec 2023. However, in Mar 2024, the company had a net cash inflow of 3.14M.

The 14 days of historical data for this financial instrument is quite intriguing. The opening price on February 27th was 4.647.

On average, the closing price for the 14-day period was 4.63. This is a relatively stable price range, with only a few instances of significant variation.

The minimum price recorded during this period was 4.420 on February 11th. This is the lowest point the price reached.

The maximum price was 4.835 on February 17th. This is the highest point the price reached during the 14-day period.

Here are the opening and closing prices for the 14-day period:

In this section, we'll dive into the key metrics that help us understand NexImmune's financial health.

Market capitalization is a crucial metric, and in this case, it's a relatively modest $348.66K.

Enterprise value is not available for NexImmune, so we can't compare it to its market capitalization.

The price-to-earnings (P/E) ratio is a key indicator of a company's stock value, and in this case, it's a negative 0.16, indicating a potential issue with earnings.

The enterprise value to earnings before interest, tax, depreciation, and amortization (EV/EBITDA) ratio is a measure of a company's stock price compared to its cash flow, and it's 0.31 for NexImmune.

Here are the key metrics for NexImmune:

NexImmune's earnings per share (EPS) is a negative $24.14, indicating a significant loss.

The company's revenue, EBITDA, and income are not available, making it difficult to assess its financial performance.

The profit margin, operating margin, and gross margin are all 0%, indicating a lack of profitability.

The EBIT margin is also 0%, further highlighting the company's financial challenges.

Here are the profitability ratios for NexImmune:

Financial ratios are a crucial aspect of financial data, providing valuable insights into a company's performance and health. They can be used to compare a company's performance over time, as well as against its competitors.

Every financial ratio you might need is available, with a 10-year history to analyze trends and patterns. This comprehensive dataset allows for a deeper understanding of a company's financial situation.

Forward ratios, based on analysts' estimates, offer a glimpse into a company's potential future performance. This information can be invaluable for investors and analysts looking to make informed decisions.

To make the most of financial ratios, you can personalize your watchlist with companies you want to keep track of. This way, you'll receive notifications in the smart feed every time fresh news arrives, keeping you up-to-date on the latest developments.

Here are some key types of financial ratios you might find useful:

NexImmune Financial Statements provide a wealth of information about the company's financial health.

Their profit margin was 0% as of Dec 2023, indicating that they are operating at a loss.

In the same quarter, their net income was -$5.35M.

NexImmune's earnings per share (EPS) was -$24.14 as of Dec 2023.

Their cash flow was -$5.83M in Dec 2023, with a net change of -$44.44M.

Here are some key metrics from NexImmune's financial statements:

NexImmune's revenue is not available in their financial statements.